PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · Ann Natl Acad Med Sci 2021; 57(04): 202-213
DOI: 10.1055/s-0041-1731597
Review Article

A Step Toward Optimizing Regenerative Medicine Principle to Combat COVID-19

Autoren

  • Shilpa Sharma 

    1   Department of Paediatric Surgery, All India Institute of Medical Sciences, New Delhi, India

  • Madhan Jeyaraman 

    2   Department of Orthopaedics, School of Medical Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh, India

  • Sathish Muthu 

    3   Department of Orthopaedics, Government Medical College and Hospital, Dindigul, Tamil Nadu, India

  • Talagavadi Channaiah Anudeep 

    4   Department of Plastic Surgery, Topiwala National Medical College and BYL Nair Ch. Hospital, Mumbai, Maharashtra, India

  • Naveen Jeyaraman 

    5   Department of Orthopaedics, Kasturba Medical College, MAHE University, Manipal, Karnataka, India

  • Ajay Satish Shringeri 

    6   Department of Orthopedics, Sri Devaraj URS Medical College, Kolar, Karnataka, India

  • Vinodh Kumar 

    7   Biocon Biologics, Chennai, Tamil Nadu, India

  • Rajeswari Somasundaram 

    8   Department of Microbiology, PSG BioNEST, PSG TECH, Coimbatore, Tamil Nadu, India

  • Rashmi Jain 

    9   School of Medical Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh, India

  • Saurabh Kumar Jha 

    10   Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, Uttar Pradesh, India
Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

Abstract

Drugs are currently not licensed in specific to pulverize COVID-19. On an emergency basis, vaccines were approved to prevent the further spread of COVID-19. This serves as a potential background for considering the optimization of biologics. In this context, evidence on convalescent plasma and stem cells has shown a beneficial role. Here, we have considered this as plausible therapy, and further hypothesize that their cocktails will synergistically boost the immunogenicity to relegate COVID-19. This warrants a large volume clinical trial on an emergent basis, because the sooner we establish a safe and effective cure, the better.

Keywords

COVID-19 - mesenchymal stem cells - convalescent plasma - pandemic


Publikationsverlauf

Artikel online veröffentlicht:
21. Juni 2021

© 2021. National Academy of Medical Sciences (India). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India